Retatrutide Side Effects and Fertility: Trial Data

Retatrutide side effects and fertility are important considerations for anyone following this investigational medicine's clinical development. Retatrutide is an unlicensed triple receptor agonist targeting GLP-1, GIP and glucagon receptors, currently available only within authorised clinical trials. It holds no marketing authorisation in the UK, and the MHRA has not assessed it for safety, quality or efficacy. This article summarises what clinical trial data currently report about its side effect profile, what is and is not yet known about reproductive health, and the serious risks of obtaining it outside a regulated trial setting.

What is retatrutide and what is its current UK regulatory status?

Retatrutide is an investigational triple GLP-1, GIP and glucagon receptor agonist with no UK marketing authorisation; it can only be supplied within an authorised clinical trial, and the MHRA has not assessed it for safety or efficacy.

Retatrutide holds no marketing authorisation in the UK or anywhere else, meaning it is not a licensed medicine and can be supplied only within an authorised clinical trial.^[5] It is an investigational triple receptor agonist that acts simultaneously on glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon receptors. This triple mechanism is intended to influence appetite regulation, energy expenditure and glucose metabolism, though its clinical profile is still being characterised through ongoing research.

Because retatrutide has no UK marketing authorisation, the MHRA has not assessed it for safety, quality or efficacy in the way it would for a licensed product. No approval date or regulatory timeline can be given. People interested in licensed weight-management treatments should speak with their GP, who can discuss options that are currently authorised and, where appropriate, recommended by NICE. Availability of licensed treatments on the NHS depends on local Integrated Care Board (ICB) commissioning and specialist weight-management pathways, not NICE guidance alone.

The MHRA has warned about the risks of purchasing injectable weight-management products from unverified online sources.^[5] Anything sold online or through private clinics as retatrutide is not a licensed product and may be falsified, adulterated or of unknown composition. Purchasing such products carries serious health risks and is outside any regulated safety framework.

What side effects have been reported in retatrutide clinical trials?

Clinical trials report gastrointestinal effects (nausea, vomiting, diarrhoea, constipation) as the most common side effects, with serious events including acute pancreatitis, heart rate increases and gallstones also documented.

The side effects reported with retatrutide in clinical trials have been broadly consistent with those seen across the GLP-1 receptor agonist class, with gastrointestinal effects being the most common. In the Phase 2 trial published in the New England Journal of Medicine (2023), the most frequently reported adverse events included nausea, vomiting, diarrhoea and constipation.^[1] These effects were generally dose-dependent and most pronounced during dose escalation.

The Phase 3 TRIUMPH programme (TRIUMPH-1 through TRIUMPH-4) is providing a larger and more detailed safety dataset across broader populations.^[3] Findings from the TRANSCEND-T2D-1 study, published in The Lancet, have added further information on the safety profile in people with type 2 diabetes.^[2] As with other medicines in this class, injection-site reactions, decreased appetite and fatigue have also been noted.

More serious adverse events reported in trials include:

• Acute pancreatitis: Cases have been reported, and participants with a history of pancreatitis are typically excluded from trials.^[1]

• Heart rate increases: Modest elevations in resting heart rate have been observed; this may be associated with GLP-1 receptor agonism, consistent with observations reported in the labelling of authorised medicines in this class.

• Gallbladder-related events: Cholelithiasis (gallstones) has been reported and may be associated with rapid weight loss, consistent with class observations in the labelling of authorised GLP-1 receptor agonists.

• Hypoglycaemia: Particularly relevant in participants with type 2 diabetes using concomitant insulin or sulphonylureas.

If you are taking part in a retatrutide trial and experience severe, persistent abdominal pain with or without vomiting, or are unable to keep fluids down, seek urgent medical attention by calling 999 or going to your nearest accident and emergency department. Inform the emergency team that you are enrolled in a clinical trial and contact your trial team as soon as possible. Adverse events in trials are reported to the trial team under the study protocol. Suspected side effects of any medicine can also be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Because retatrutide is investigational, its full safety profile is not yet established.

Could retatrutide affect fertility, pregnancy or reproductive health?

No human evidence currently exists on retatrutide's effects on fertility or pregnancy; pregnant and breastfeeding individuals are excluded from trials, leaving reproductive safety entirely uncharacterised.

There is currently no established evidence from human studies on whether retatrutide affects fertility, and this remains an area of active investigation within the clinical trial programme. As an investigational medicine, retatrutide has not been assessed by the MHRA for reproductive safety, and no conclusions about its effects on human fertility can be drawn from the available data.

Participants who are pregnant, breastfeeding or planning a pregnancy are excluded from retatrutide clinical trials. This exclusion is standard practice for investigational medicines where reproductive and developmental safety has not been characterised. It means that the trials do not generate data on outcomes in pregnancy or during lactation, and the effects of retatrutide on a developing foetus or on breast milk composition are unknown.

People who could become pregnant and who are enrolled in retatrutide trials are required to use effective contraception throughout participation and for a defined period after the last dose, in line with standard trial protocols for investigational medicines. The specific contraception requirements are set out in each trial's protocol and should be discussed directly with the trial team.

For context, licensed GLP-1 receptor agonists carry advice against use in pregnancy and during breastfeeding.^[4] Some authorised medicines in this class, such as tirzepatide, require additional contraceptive precautions during dose escalation owing to potential effects on oral contraceptive absorption; this is documented in the relevant UK Summary of Product Characteristics and BNF interactions guidance.^[8][9] Whether similar considerations would apply to retatrutide if it were ever authorised cannot be determined from current data. Anyone with questions about reproductive health and weight-management medicines should speak with their GP.

Who was included in trials, and what do the results not yet tell us?

Trials have enrolled adults with obesity or type 2 diabetes, but long-term cardiovascular outcomes, reproductive effects, and safety in adolescents or those with severe organ impairment remain unknown.

The Phase 2 retatrutide trial enrolled adults with obesity or overweight and at least one weight-related comorbidity, excluding people with type 1 diabetes, recent cardiovascular events, and those who were pregnant, breastfeeding or planning pregnancy.^[1] The TRIUMPH Phase 3 programme and TRANSCEND-T2D-1 have broadened the study populations to include people with type 2 diabetes and those at higher cardiovascular risk, but important groups remain underrepresented or excluded. Trial identifiers and status information for the TRIUMPH studies are available at ClinicalTrials.gov.

What the current evidence does not yet tell us includes:

• Long-term cardiovascular outcomes: Dedicated cardiovascular outcome trials are ongoing; no results are yet publicly available.

• Effects in adolescents or older adults: Most trial participants fall within a defined adult age range.

• Reproductive and fertility outcomes: As noted above, pregnant and breastfeeding individuals are excluded, leaving this area uncharacterised.

• Effects in people with severe renal or hepatic impairment: These groups are typically excluded from early-phase trials.

• Very long-term safety beyond trial duration: The durability of any effects and the safety profile over many years remain unknown.

Trial findings are reported for defined populations over defined periods and cannot be generalised to all people who might eventually use the medicine. The TRIUMPH and TRANSCEND programmes are expected to provide substantially more data, but retatrutide remains investigational and no public announcement of a regulatory submission in the UK has been identified.

What are the risks of obtaining retatrutide outside a clinical trial?

Obtaining retatrutide outside an authorised trial is illegal in the UK; products sold through unregulated routes may be falsified, contaminated or contain entirely different substances, posing serious health risks.

Obtaining retatrutide outside an authorised clinical trial carries serious and potentially life-threatening risks, because any product sold through this route is not a licensed medicine and may be falsified, contaminated or of entirely unknown composition. Retatrutide can be supplied only within an authorised clinical trial; there is no legal or regulated route to obtain it privately in the UK.

Products sold online or through unregulated clinics as retatrutide may contain:

• No active ingredient at all, making them ineffective.

• Incorrect or unknown doses, which could cause unpredictable pharmacological effects.

• Harmful contaminants or excipients, including microbial contamination from non-sterile manufacture.

• Entirely different substances, including other peptides or compounds not intended for human use.

Because such products fall outside any regulatory framework, there is no regulated quality or safety oversight. If someone experiences a serious reaction after using an unregulated product, they should call 999 or go to the nearest accident and emergency department immediately. For non-emergency concerns, NHS 111 can provide advice.

The MHRA actively monitors the supply of unlicensed and falsified medicines. Anyone who believes they have purchased a falsified medicine should report it to the MHRA. Licensed weight-management treatments are available through regulated NHS and private routes, and a GP is the appropriate starting point for a discussion about which options may be suitable. Availability on the NHS depends on local ICB commissioning and specialist weight-management pathways.

Scientific References

1. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2 Trial.
2. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in type 2 diabetes (TRANSCEND-T2D-1).
3. Retatrutide for the treatment of obesity, obstructive sleep apnoea and related conditions — TRIUMPH Phase 3 programme overview.
4. GLP-1 medicines for weight loss and diabetes: what you need to know.
5. MHRA urges public to avoid illegal online weight-loss medicines.
6. The Yellow Card scheme: guidance for healthcare professionals, patients and the public.
7. Adverse reactions to drugs — BNF.
8. Tirzepatide interactions — BNF.
9. Tirzepatide — BNF.
10. The impact of tirzepatide and glucagon-like peptide-1 receptor agonists on oral contraceptive absorption.
11. Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial.
12. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial.

Frequently Asked Questions